Results 31 to 40 of about 6,309 (194)
Tafamidis in transthyretin amyloid cardiomyopathy [PDF]
Clinical pharmacology and therapy, 2021 Transthyretin is primarily synthesized in the liver and transports thyroxine and vitamin A in the body. The transthyretin when dissociated into monomers can misfold and ultimately form amyloid fibrils. There are two types of ATTR amyloidosis: hereditary (caused by mutations in the TTR gene) and wild-type (also referred to as senile systemic amyloidosis)
S. Moiseev, V. Rameev
openaire +1 more source
Tafamidis for the Treatment of Transthyretin Amyloidosis [PDF]
Future Cardiology, 2019 Transthyretin (TTR) related cardiomyopathy is an underdiagnosed cause of heart failure but is increasingly recognized in various settings - from patients admitted with heart failure to symptomatic aortic stenosis - and is rapidly becoming the most frequent form of systemic amyloidosis.
Lorenzini, M, Elliott, PM
openaire +3 more sources
Frontiers in Medicine, 2022 IntroductionAnginal symptoms and signs of ischemia have been reported in some patients with cardiac transthyretin amyloidosis (ATTR) without obstructive epicardial coronary artery disease (CAD).
Bastien Vançon +8 more
doaj +1 more source
Corino de Andrade disease: mechanisms and impact on reproduction [PDF]
, 2017 Familial amyloid polyneuropathy was first described by Corino de Andrade in 1952 in Northern Portugal. It is a fatal autosomal dominant neurodegenerative disorder characterized by a progression of neurologic symptoms, beginning early in the reproductive ...
Barros, A. +3 more
core +1 more source
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
Frontiers in Cardiovascular Medicine, 2023 An increasing awareness of the disease, new diagnostic tools and novel therapeutic opportunities have dramatically changed the management of patients with amyloid transthyretin cardiomyopathy (ATTR-CM).
Daniela Tomasoni +17 more
doaj +1 more source
Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide [PDF]
, 2018 The aim of this study is to assess the prevalence of cardiac involvement in hereditary transthyretin-derived (ATTRm) amyloidosis at the time of diagnosis and to determine the diagnostic and clinical value of N-terminal pro-B-type natriuretic peptide (NT ...
Blokzijl, Hans +7 more
core +2 more sources
Methodist DeBakey Cardiovascular Journal, 2022 Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications.
Lily K. Stern, Jignesh Patel
doaj +1 more source
A biophysical approach to the identification of novel ApoE chemical probes [PDF]
, 2019 Alzheimer’s disease (AD) is the most common type of dementia and, after age, the greatest risk factor for developing AD is the allelic variation of apolipoprotein E (ApoE), with homozygote carriers of the ApoE4 allele having an up to 12-fold greater risk
Burgess +8 more
core +3 more sources
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy [PDF]
, 2021 BACKGROUND: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in ...
Drachman, BM +10 more
core +1 more source
Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. [PDF]
Eur J Heart FailLong‐term efficacy of tafamidis in patients with ATTR‐CM in ATTR‐ACT and its LTE by NAC stage at ATTR‐ACT baseline. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR‐CM, transthyretin amyloid cardiomyopathy; NAC, National Amyloidosis Centre.
Damy T +4 more
europepmc +2 more sources